SecBot SecBot
SECBOTREPLAY Home › Report › PRAX

PRAX · Praxis Precision Medicines announced positive topline results from the…

Praxis Precision Medicines, Inc. · PRESS-RELEASE filed Apr 6, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 6, 2026 at 08:00 ET

Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with SCN2A developmental and epileptic encephalopathy (DEE), showing a 77% placebo-adjusted seizure reduction (p=0.015) and meaningful functional improvements across sleep, motor function, and attention. The drug was well-tolerated with no drug-related serious adverse events, supporting its potential as a first disease-modifying therapy for this rare genetic epilepsy.

  • Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in SCN2A-DEE patients
  • 71% of treated patients had >50% seizure reduction; 57% had at least 28 days seizure-free
  • 100% of elsunersen patients showed functional improvements vs. none in placebo
  • No treatment-emergent or serious adverse events related to the drug

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access